Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.05
Bid: 3.80
Ask: 4.30
Change: 0.15 (3.85%)
Spread: 0.50 (13.158%)
Open: 3.90
High: 4.05
Low: 3.72
Prev. Close: 3.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

Thu, 23rd Sep 2021 11:48

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Harbour Energy PLC - North Sea-focused oil and gas company - Returns to pretax profit of USD120.2 million in six month ended June 30 from USD224.3 million loss year prior. Revenue jumps to USD1.4 billion from USD1.2 billion. Other income increases to USD119.3 million from USD13.6 million. Says it will update its dividend policy early December. Reiterates production guidance of 170,000 to 180,000 barrels of oil equivalent per day for financial 2021. Expects higher production in second half of financial year. "The extended maintenance programmes which impacted our production have completed, drilling activity has returned to pre-Covid-19 levels and the merger integration is progressing well, all underpinning strong future cash flow generation," company adds.

----------

Fonix Mobile PLC - London-based mobile payments and messaging provider - Pretax profit rises to GBP7.4 million in 12 months to June 30 from GBP7.2 million a year earlier. Revenue increases to GBP47.7 million from GBP40.1 million. Cost of sale rise to GBP36.3 million from GBP30.1 million. Recommends final dividend of 3.53p per share. Sees positive start to financial 2022, with trading in line with expectations. Declared maiden interim dividend of 1.7p in February. "With a strong entry run-rate, along with new client wins, a key new technology partnership and new market connectivity, the Board continues to be confident in the business's growth potential and increasing profitability," company says.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Sees pretax profit for financial year to June 30 sink to GBP3.7 million from GBP8.1 million last year. Revenue rises to GBP84.3 million from GBP78.2 million. Administrative expenses rise to GBP33.6 million from GBP25.5 million, while cost of sales increase to GBP22.1 million from GBP20.2 million. "The coming year will see further investment in the group's infrastructure as the business matures as a well-established and growing European business. The group also continues to invest in its pipeline of next generation allergy immunotherapeutics. Upcoming results from the Grass MATA MPL exploratory field study, the pre-investigational new drug application meeting with the US Food & Drug Administration for VLP Peanut, followed by the commencement of the Phase 1 trial in the US are all promising and exciting developments and set the course for the future of the business," company says.

----------

Arecor Therapeutics PLC - Cambridge, England-based biotechnology company - Reports widened pretax loss of GBP3.5 million in six months to end June from GBP1.3 million last year. Revenue sinks to GBP460,021 from GBP817,043. Company says: "We have made tremendous progress across the business during the first six months of the year with key highlights including our successful IPO on AIM and, earlier this week, positive results from the Phase I clinical trial for our ultra-concentrated ultra-rapid acting insulin, AT278, the second product in our diabetes franchise...With the GBP20 million raised, we are now well-placed to rapidly advance our proprietary pipeline with further clinical trials for our lead products planned in the coming year."

----------

Distribution Finance Capital Holdings PLC - Manchester-based bank providing personal savings products - Pretax loss narrows to GBP2.3 million in six months to June 30 from GBP7.2 million. Net income rises to GBP5.3 million from GBP2.0 million. Loan book rises to GBP166.8 million from GBP165.9 million. "Despite the widely publicised impact of the pandemic on manufacturers and supply chains, the current pipeline of product scheduled to be delivered to dealers over the coming months underpins the board's expectation that the group will achieve run-rate profitability on a monthly basis during the fourth quarter of 2021," company says. Continues to evaluate both organic and inorganic opportunities, as well as partnerships.

----------

Venture Life Group PLC - Bracknell, England-based maker and distributor of self-care products - Swings to pretax loss in six months to June 30 of GBP40,000 from GBP2.1 million profit year-on-year. Revenue falls to GBP13.9 million from GBP16.9 million. Does not pay dividends. "The first half of 2021 was a challenging trading environment for the group, as another extended Covid lockdown affected customers and suppliers in many countries. Despite this, the group saw growth in its core business revenues...with the current order book ahead of the same time last year on an actual and like for like basis, and two immediately earnings acquisitions (one post period end). These acquisitions are expected to add materially to the revenues and profitability for 2021 and the future, as well as providing new therapy areas and products for the group to expand and develop further," company says. Buys diabetes management company BBI Healthcare Ltd for around GBP36 million in June.

----------

Cornish Metals Inc - miner with assets in Cornwall - Posts widened loss for six months to July 31 of CAD1.1 million, about GBP635,000, from CAD789,476 a year prior. Expenses rise to CAD455,393 from CAD344,336. "The past six months has been a busy period for the company after the successful listing on AIM [in February]. The company's capital structure has been simplified through the conversion of the Osisko loan note into royalties and the restructuring of the deferred consideration payable in respect of the acquisition of the Cornwall mineral properties into fixed payments linked to project related milestones," company says. "We are assessing various financing options to progress South Crofty which remains a key strategic asset for the company. South Crofty could potentially play a pivotal role in securing a domestic and sustainable source of battery metals as the UK transitions to a low carbon economy," company adds.

----------

Attraqt Group PLC - London-based software for online shopping - Loss before tax in six months to June 30 widens to GBP1.8 million from GBP1.3 million. Revenue rises to GBP11.1 million from GBP10.2 million. Cost of sales increases to GBP3.0 million from GBP2.7 million. "We are continuing to implement our strategy to address the mid-market growth opportunity with deep integrations to ecommerce platforms. Revenue is trading in line with expectations for the full year on a constant currency basis and we are confident we have the right strategy and the right technology to drive the business forward," company says. Adds that it will focus on paying dividends in future.

----------

Ormonde Mining PLC - gold explorer in Spain - Swings to pretax loss of EUR630,000 in six months ended June 30 from EUR1.2 million profit a year ago. Administrative expenses increase to EUR617,000 from EUR436,000. Company is not revenue generating. Says investigation permits for Salamanca and Zamora gold projects are in the process of being renewed. Plans to sell La Zarza asset.

----------

Ebiquity PLC - London-based marketing and media consultancy - Pretax loss in six months to end June narrows to GBP1.1 million from GBP1.7 million last year. Revenue increases to GBP32.0 million from GBP26.8 million. Says progress expected to continue in the second half of the year, although macro-environment remains uncertain. Does not declare interim dividend, unchanged from last year. Adds that digital media unit is continuing to grow its client base and revenue. Expects full year underlying operating profit to be slightly above previous expectations.

----------

Velocys PLC - Oxford-based fuels technology company - Pretax loss in six months to June 30 narrows to GBP2.2 million from GBP2.7 million last year. Revenue increases to GBP8.2 million from GBP180,000. Cost of sales rises to GBP4.9 million from GBP106,000, while operating expenses increase to GBP5.4 million from GBP2.8 million. "The final stage of preparing the US Bayou Fuels project for its FEED fund raise is underway to take advantage of increased investor appetite for advanced fuel decarbonisation technologies in the US alongside achieving the best possible technical readiness to commence FEED. Velocys is targeting completion of fuel offtake agreements for the project ahead of completion of substantial third-party FEED project funding which is currently expected in the first half of 2022."

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Sep 2019 11:26

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Read more
27 Jun 2019 10:07

Allergy Therapeutics earnings set to top expectations

(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.

Read more
19 Jun 2019 13:39

Allergy Therapeutics Hires Former Advanced Medical Solutions CFO

(Alliance News) - Allergy Therapeutics PLC on Wednesday said it has appointed Mary Tavener as a non-executive director with immediate effect.The biotechnology company said Tavener has in 19

Read more
20 May 2019 13:42

Allergy Therapeutics Vaccine Helps Dust Mite Allergy Symptoms In Study

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.The AM101 study, which was open-label

Read more
20 May 2019 11:00

Allergy Therapeutics flags positive outcomes from recent treatment trial

(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.

Read more
25 Apr 2019 10:01

Allergy Therapeutics eyes 2020 start for hay fever inoculation trials

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.

Read more
18 Mar 2019 10:44

WINNERS & LOSERS SUMMARY: Footasylum Rises On "Generous" JD Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - Tinto, up 2.3%, Group, up in

Read more
18 Mar 2019 10:06

Allergy Therapeutics Surprised As Vaccine Trial Fails Primary Endpoint

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said a phase three trial of its birch pollen allergy vaccine did not meet its primary endpoint.Shares in Allergy Therapeutics 43%

Read more
18 Mar 2019 08:51

Allergy Therapeutics shares plunge after disappointing clinical trial

(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.

Read more
6 Mar 2019 11:13

Allergy Therapeutics Interim Profit Rises 67% On Higher Revenue

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday reported significantly higher profit for the first six months of its financial year as revenue rose and research costs were the to of

Read more
6 Mar 2019 10:19

Allergy Therapeutics profits rise as it spends less on R&D

(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.

Read more
16 Jan 2019 12:26

Allergy Therapeutics First Half Meets Forecasts On European Growth

LONDON (Alliance News) - Allergy immunology vaccines developer Allergy Therapeutics PLC said Wednesday trading in the first half was in line with expectations.Allergy Therapeutics expects -

Read more
16 Jan 2019 08:51

Allergy Therapeutics sees good first-half progress

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.

Read more
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.